*Good Morning*
• India’s April Retail Inflation Eases as Food Prices Slow
• India March Industrial Production Rises 22.4% Y/y, Est. +20.0%
• India April Consumer Prices Rise 4.29% Y/y, Est. +4.10%
• India to Give $2.5B in Incentives to Battery-Storage Production
• Suzuki Unsure on Outlook With Covid Rampant in Biggest Market
• Advent Said to Mull ASK Group Stake Sale at $1 Billion Value
o Buyout firm is working with Nomura to explore options
• Oxygen Shortage in India Sparks Global Hunt for $1,000 Machines
o Philips says it has ‘significantly’ increased global output
• Guinea’s Bauxite Exports Rise 5% in 1Q to 22 Million Tons: Govt
• India 2020-21 Edible Oil Imports Seen Falling 3.3% y/y: Bajoria
• Businesses Offer Employees Time ‘to Heal’ as Virus Ravages India
• Equity Mutual Fund Outflows Narrow to $5.44 Billion: ICI
• Global Funds Sell Net INR12.6B of India Stocks on May 12: NSE
o Domestic funds sell net 7.04b rupees of stocks
• Foreign Investors Buy Net INR7.16B of Indian Equities on May 11
• Foreigners Buy Net INR69.1B Indian Equity Derivatives Wednesday
• IMD issues cyclonic storm warning, predicts heavy rainfall: PTI
• SC to hear Chardham highway project matter on Friday: PTI
• ONGC removes marketing margin but refuses to lower gas price: PTI
• SoftBank to No Longer Sell SB Energy Stake to CPPIB: Mint
• 12pm: India April Wholesale Price Inflation YoY, est. 9.50%, prior 7.39%
• 05/14-05/15: India April trade balance, est. -$15.2b, prior -$13.9b
o India April Exports YoY, no est., prior 60.3%
o India April Imports YoY, no est., prior 53.7%
• Apollo Tyres (APTY): 4Q net income 2.87b rupees vs. 778.6m y/y, beats est. 2.27b; revenue +39% to 50.3b
• Asian Paints (APNT): 4Q net income +84% y/y to 8.52b rupees, beats est. 8.26b; revenue +43% to 66.5b, est. 60.08b
• Ashapura Minechem (ASMN): Guinea’s Bauxite exports rise 5% in 1Q to 22m tons: Govt
• Bosch India (BOS): Suspends operations at Nashik plant May 12-23
• Eicher Motors (EIM): Says Royal Enfield plant to be shut May 13-16, to undertake maintenance activity
• Hindustan Construction Co. (HCC): Says HCC-KEC International (KECI) Jv. wins 11.47b rupees order from Chennai Metro Rail
• Jindal Steel (JSP): 4Q net income19.7b rupees vs. 1.83b y/y, misses est. 27.9b; Revenue +75% to 118.8b
• KEC International (KECI): Wins new orders of 15.14b rupees across its various businesses
• Pidilite Industries (PIDI):4Q net income +95% y/y to 3.06b rupees, +95% y/y, meets est. 3.05b; Revenue +45% to 22.4b
• Tata Power (TPWR): 4Q net income 3.93b rupees, est. 3.87b, revenue 101.3b rupees, est. 87.7b; Approves raising up to INR55b Via debentures
• UPL Ltd. (UPLL): 4Q net income +72% y/y to 10.6b rupees, misses est. 10.78b, revenue +15% to 128b; Ebitda 28.4b, beats est. 25.57b
• Vedanta (VEDL): 4Q net income 64.32b rupees vs. loss 125.21b y/y, beats est. 39.89b; Sales +43% to 278.74b

*SGX Nifty -33 pts (14676) from WEDNESDAY'S last trade 14709*

Nikkei +414 pts,
Hangseng +154 pts,
Now @6.52am.

Dow +433.79 pts ,Nsdq +93.31 pts, S&P +49.46 pts, Bovespa +995 pts , Ftse -41 pts , Dax +49 pts , Cac +8 pts , Crude @ $63.84 brl (+0.02), Brent @ $67.05 brl (+0.00) , Gold @ 1825.60 (+1.70), Silver @ $27.145 (+0.08), Euro @ $1.2075, JPY @ $109.51  INR @ 73.445

*Today's Corporate Action*
*14th May Ex Date*
None

*Today's Key Results/Board Meetings*
*14-May-21*
ANUP
Audited Results; Final Dividend

ASTAR
Audited Results; Final Dividend

BALKRISIND
Audited Results; Final Dividend

BCPL
A.G.M.; Audited Results; Final Dividend; General; Quarterly Results

BHARATSE
Audited Results; Final Dividend

CHOLAHLDNG
Audited Results

CIPLA
Audited Results;Dividend; Quarterly Results

DECNGOLD
Audited Results

DRCSYSTEMS
Audited Results; General

DRREDDY
Audited Results; Final Dividend

ESCORTS
Audited Results; Final Dividend; General; Quarterly Results

GICRE
General

GOKEX
Audited Results

GREENPANEL
Audited Results

HIKLASS
Audited Results

HIL
Audited Results; Final Dividend

INDIGOPNTS
Audited Results; Quarterly Results

JSL
Audited Results

KARTKIN
Audited Results

KESORAMIND
Audited Results; General

LODHA
Audited Results; Quarterly Results

LT
Audited Results; Dividend

MENONBE
Audited Results

MINDSPACE
Audited Results; Interim Dividend

MONTECARLO
Audited Results; Dividend

OCTAL
Audited Results

ONWARDTEC
Audited Results; Final Dividend

PRIVISCL
Audited Results; Final Dividend

QGO
A.G.M.; Audited Results; General; Quarterly Results

ROSSARI
Audited Results; Final Dividend

SAGARSOFT
Audited Results; Dividend; Issue Of Warrants; Preferential Issue of shares; Quarterly Results

SAINTGOBAIN
Audited Results; Final Dividend

SKFINDIA
Audited Results; Dividend; Quarterly Results

SURBHIN
Quarterly Results

TEXINFRA
Audited Results; Dividend; General; Quarterly Results

TEXRAIL
Audited Results; Dividend; General; Quarterly Results

VIMTALABS
Audited Results; Dividend; Employees Stock Option Plan

*Stock under F&O ban on NSE*
*14-May-21*
1BHEL
2CADILAHC
3CANBK
4PNB
5SUNTV

Economic Times

Business Standard

Ø RBI tells lenders to re-consider ties with crypto exchanges, traders
Ø Govt eases public procurement norms for Covid supplies
Ø Commerce Ministry seeks anti-dumping duty on certain rubber imported from 4 countries
Ø Tata Sons, Singapore Airlines invest Rs 465 crore in Vistara
Ø RBI cancels United Co-operative Bank's licence
Ø Auto retailers' lobby writes to FM, RBI governor to request loan moratorium

Ø India received $83 billion in remittances in 2020: World Bank report
Ø Torrent Pharma inks pact with Eli Lilly for Covid drug Baricitinib in India
Ø South Korea unveils $450 billion push for global chipmaking crown
Ø Musk decries bitcoin's 'insane' energy use after Tesla payment U-turn
Ø Vedanta swings into the black; posts Rs 6,531 cr profit in March quarter

Business Line

Mint

Ø TRAI floats consultation paper on validity period of tariff offers
Ø Overall passenger traffic plunges 66% in FY21, AAI data shows
Ø CRISIL assigns A+/Stable rating to long-term credit facilities of Jindal Stainless
Ø PE/VC investments grow 6.5x to $7.5 billion in April over year-ago period
Ø Lupin Q4 net rises 18% at ₹460 cr

Ø Piramal Enterprises Q4 net loss narrowed to ₹510 crore
Ø BSE clocks Q4 net profit of ₹31.75 crore; revenue up 27 per cent
Ø Blue Dart forms Med-Express consortium to conduct experimental drone flights
Ø Bitcoin still struggling after Musk's Tesla U-turn
Ø Jack Ma’s Ant posted $3.4 billion profit after IPO halt
Ø CPPIB and SoftBank’s SB Energy deal called off

Financial Express

Business World

Ø India’s prized ‘investment grade’ status hanging by a thread due to devastating COVID-19 crisis
Ø Jio tops in 4G download speed, Vodafone in upload in April: Trai

Ø FPIs' Investment In Domestic Equity Surges 7 Pc To USD 552 Bn In Mar Qtr
Ø Intense Bidding For KG-D6 Gas In E-Auction On DGH-Approved Platform

Trading Tweaks

Ex-Date AGM: Uniply Industries

Record Date Special Dividend: Gillette India

Record Date Interim Dividend: NCL Industries

Price Band Revised From 10% To 5%: Bajaj Hindusthan Sugar, Jaiprakash Power Ventures, KIOCL, Sastasundar Ventures

Price Band Revised From 20% To 10%: Shriram EPC

Move Into Short-Term ASM Framework: Gufic Biosciences, Southern Petrochemicals Industries Corporation,Kopran, Uniphos Enterprises, TD Power Systems, Shalby, Reliance Infrastructure, Nalwa Sons Investments, Filatex India, Macrotech Developers, Bajaj Hindusthan Sugar

Move Out Of Short-Term ASM Framework: Andhra Sugars, Jubilant Ingrevia, Shree Renuka Sugars, Tata Metaliks, Gujarat Ambuja Exports, Reliance Power

Move Into ASM Framework:Reliance Power, Everest Kanto Cylinder, Shriram EPC, Trident, Jayaswal Neco Industries

Pledge Share Details

JSW Energy: Promoters (JSW Investments and Indusglobe Multiventures) revoked pledge of 50.65 lakh shares between May 7-10. Promoter Siddheshwari Tradex created a pledge of 30 lakh shares on May 10.

Steel Strips Wheels: Promoters (Dheeraj Garg, DHG Marketing and SAB Industries) revoked pledge of 9.24 lakh shares between February 16 and March 2.

Sun Pharmaceutical Industries: Shanghvi Finance revoked pledge of 31.08 lakh shares on February 11.

Stocks To Watch

Royal Enfield: To temporarily halt production at its manufacturing facilities in Chennai for four days over rising Covid-19 cases. The company’s manufacturing operations across Thiruvottiyur, Oragadam & Vallam Vadagal to remain shut between May 13-16. It will undertake maintenance activity at production facilities. The company does not foresee any significant impact on its ability to cater to the demand.

Equitas Small Finance Bank: Lockdowns to impact May collections. April billing efficiency stood at 84.68%. April collection efficiency stood 105.16%.

KEC International: Has secured new orders of Rs 1,514 crore across its various businesses. The company has secured orders of Rs 326 crore for Transmission & Distribution projects and orders of Rs 153 crore for various types of
cables. The company has secured orders of Rs 1,035 crore for the construction of an elevated viaduct along with stations for a metro project and for mechanical & civil works in two cement plants.

Tata Power: Approved issuance of listed NCDs up to an aggregate amount of Rs 5,500 crore. The funds raised will be utilised for refinancing existing loans.

Torrent Power: Board to consider raising up to Rs 2,000 crore by issuance of NCDs through private placement basis.

Nifty Earnings: Larsen & Toubro, Cipla, Dr Reddy's Laboratories

Non-Nifty Earnings: Escorts, Rossari Biotech, Macrotech Developers, Mindspace Business Parks REIT, Anup Engineering, Asian Star Co, Balkrishna Industries, Cholamandalam Financial Holdings, Greenpanel Industries, HIL, Indigo Paints, Jindal Stainless, Kesoram Industries Monte Carlo Fashions, Privi Speciality Chemicals, Saint-Gobain Sekurit India, SKF India, Texmaco Infrastructure & Holdings, Texmaco Rail & Engineering, Vimta Labs

Stocks Ban In F&O:
Bhel,
Cadila,
Canara Bank,
PNB,
Sun TV

*STOCKS TO WATCH: BIRLA CORP, LUPIN, VEDANTA, TATA POWER, PRINCE PIPES, APOLLO TYRES, KEC INTL, JINDAL STEEL & POWER, PIDILITE, POLYCAB, H.G INFRA, ORIENT ELECTRIC,IND SWIFT LAB,SHREYANS IND,DVL, UPL,SPIC, ORIENT PAPER,RUBY MILLS*

World Markets

Dow + 434
Nasdaq + 93
Dax + 49
Nikkei + 385
Hangseng + 114
Sgxnifty - 17 (14692)
Brent Crude 66.97
Dow Fut + 85
Dollar Index 90.8

*SARDA ENERGY & MINEREALS*

CO HAS APPROVED EXPANSION PROJECT OF FERRO ALLOYS BY WAY OF ADDING ONE MORE FURNACE OF 36 MVA WITH AN ESTIMATED CAPEX OF 135 CRS,EARNINGS AND ESTIMATES L: CO ANNOUNCES COLLABORATION WITH MEIJI FOR EXCLUSIVE ACCESS TO FLUPYRIMIN RICE IN SOUTHEAST ASIA

Apollo Tyres - Strong demand & cost focus drive margin beat (Antique)

Apollo Tyres (APTY) reported strong revenue growth and EBITDA margin performance in its Indian and European operations. Consolidated EBITDA grew 70% YoY to INR 8.1bn, which was 5% ahead of our expectations due to better than expected margin in European operations. In the domestic market, demand visibility is low in the near-term due to Covid-19 related restrictions, but we expect sales to improve from 2QFY22E and grow strongly in FY22E. APTY's domestic operation is well poised for a robust revenue growth (17% CAGR over FY21-23E), led by cyclical upturn in CV and PV OEM demand and strong replacement demand. The company is well placed to leverage the demand recovery, with investments in capacities, R&D, brand building, rural distribution network, etc. APTY has gained 350bp market share in OTR and PCR segments and ~150bps in TBR segment in FY21, partly aided by restrictions on import of tyres into the country. Raw material prices have increased significantly in the recent months, which will have an adverse impact on profit margins despite the price increases taken by the company. APTY has successfully completed Enschede (Netherland) plant specialization, which has resulted in significant improvement in cost competitiveness and profit margins for its European operations. As Apollo is approaching the end of its capex cycle in FY22E, we expect it to generate positive FCF, de-leverage balance sheet and improve return ratios over the next three years. We maintain BUY rating with a price target of INR280 (15x FY23E PER).

*Happiest Minds Technologies Ltd.* Concall Update
(Nirmal Bang Retail Research)
*Outlook – Neutral*
FY22 – Management has guided for organic revenue growth of 20% in medium term. With acquisition , growth of FY 22 would be higher
Management guided for a sustainable margin of 22-24% even when some operating cost could return in near term
FY21 the company had revenue growth of 10.8% and Ebitda margins of around 24.5%
• Dollar revenue came at $ 30.2 mn vs QoQ $ 26.2 mn. Of this organic revenue growth came in at 8.9%. The company had 3 months revenue impact of its acquisition Pimmcore services
• EBITDA Margin came at 25.3% vs QoQ 26.6%. Dip in margin was due to wage hike impact of Rs 9 cr .
• FY22 tax rate is expected to be around 20-24% tax rate
• Utilisation will be maintained in the range of 77-80% going ahead
• Adj. PAT came at Rs. 36.1 Cr
• Quarter EPS is Rs. 2.5 Share is trading at P/E of 78x Q4 annualised EPS

*Lupin – Q4FY21 Concall Update – Nirmal Bang Sec.*
*Outlook – Positive*
The management’s commentary was positive related to business outlook and profitability. EBITDA margins are likely to improve to 19% in FY22 from 17.8% in FY21 (including fx and other income) and further to 21-23% in FY23*

The stock is trading at 31.8x FY22E consensus earnings

Seasonally soft India business and weak US sales (-5.3% yoy) due to poor flu season led to lower overall sales for the quarter. However due to favorable product mix and cost measures, the company is witnessing improvement in margins for past 5 consecutive quarters and likely to continue the trend going forward.
*_US Business_* - the segment was down 10% yoy in cc FY21 at $720 mn vs $800mn. During the year, the company has launched Albuterol and currently enjoys 8% market share. it has not seen any change in the market dynamics post Sandoz’s entry as pricing remains stable. The management has guided that it has increased the supplies and it would visible in higher market share in coming quarters. It maintains its long-term market share target of 20%. Lupin has launched 15 products in FY21. gSpriva is expected to be launched in FY23 (court ruling in expected in mid-FY22). Lupin had to get out of market of Fortamet and Glumetza however it re-entered within a quarter. It currently holds 50% market share in Glumetza however pricing is very different. It has not yet launched Fortamet. Market share in Levothyroxin continues to improve – stands at 18.7% in Q4 vs 12% in Q3. Lupin is also in process of launching Revlimid by CY22. Going forward, in 1H competition in famotidine may impact growth in H1 however overall FY22 growth would led by ramp up in gBrovana, Alubterol. The management also reiterated that portfolio rationalisation is behind the company as the outlook for pricing is stable.
*_India_ is likely to grow by double digit in FY22*
*_API_* saw lower sales due to decline in offtake of flu related drugs. The segment, which has similar margins as company’s average, is likely to pick up from Q2 onwards
*_ROW_* sales was impacted to covid related supply issues. The segment is likely to improve with the normalisation in the overall situation
*R&D* as percent to sales is likely to come down in coming quarters.

*Piramal Enterprises Ltd. Q4FY21 Concall Update*
(Nirmal Bang Securities)

*Outlook: Neutral in near term; Positive in long term*

*Financial Services*
• Second wave of covid is not likely to have the same impact that it had in Q1FY20 but more like Q2FY20. Situation of developers is far better compared to Q1FY20.
• O/S Loan Book came at Rs. 44,668 Cr (QoQ -4%, YoY -12%). Wholesale book came at Rs. 39,365 Cr (YoY -23%)
• GNPA cam at 4.5% vs QoQ 3.7% & YoY 2.4% majorly due to movement from stage 2 to stage 3 and also due to reduction in total loan book.
• Restructured book is same as Q3 at Rs. 1741 Cr (3.9% of AUM)
• Co holds total provisions of Rs. 2800 Cr (6.3% of AUM) which it feels is enough to handle any adverse impact.
• Retail mix to increase from 12% to 50% via (i) organic growth, (ii) acquisition of DHFL, (iii) reduction in wholesale book.
• NCLT should clear the DHFL acquisition in two months post which the acquisition will be closed.
• Networth of financial services of Rs. 18,073 Cr will be enough to drive growth of around 20-25% for next 5 years in lending business and co wont require any more funds.
• *Unallocated capital of Rs. 11,029 Cr will remain unallocated and wont be used in financial services or pharma for the forseable future.*
• Exposure to Lodha has reduced to Rs. 2150 Cr from Rs. 3120 Cr as on March 2020. Of this Rs. 1530 Cr is via an SPV where PEL has 1.5x cover aganst ready inventory. Balance exposure is towards Macrotech Developer.

*Pharma*
• Revenue growth was strong at 19% YoY – a multi qtr high at Rs. 1,923 Cr.
• CDMO revenue was at Rs. 1290 Cr (+23% YoY)
• Complex hospital generics was at Rs. 507 Cr (+1% YoY)
• India consumer healthcare was at Rs. 127 Cr (+55% YoY)
• Margins remained strong at 28.6% vs YoY 29.3%
• Net debt of pharma declined to Rs. 2468 Cr from YoY Rs. 3981 Cr as the co used the funds raised from 20% dilution to the Carlyle group.
• Co is investing the funds from dilution towards expansion and acquisitions in the pharma business.
• Co would incur a capex of USD 90-100 mn over two years - FY22 & 23.
• Pharma business should grow at higher than earlier longer term guidance of 15% in FY22.

Stock is trading at P/E of 14.4x FY22E EPS. Stock implies NBFC valuation of 0.8x trailing BV, Pharma valuation of 12x TTM EV/EBITDA, Unallocated capital valuation of 1x BV.